

## REFERENCES

- Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W (2006) Disulfide isomerization switches tissue factor from coagulation to cell signaling. *Proc Natl Acad Sci U S A* 103: 13932-7
- Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD, Maruyama Y, Kobayashi M, Wood NW, Spurr NK, Burns DK, Roses AD, Saunders AM, Goldstein DB (2005) A single-nucleotide polymorphism tagging set for human drug metabolism and transport. *Nat Genet* 37: 84-9
- Aiach M, Nicaud V, Alhenc-Gelas M, Gandrille S, Arnaud E, Amiral J, Guize L, Fiessinger JN, Emmerich J (1999) Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk. *Arterioscler Thromb Vasc Biol* 19: 1573-6
- Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. *Lancet* 353: 717-9
- Albers GW (1994) Atrial fibrillation and stroke. Three new studies, three remaining questions. *Arch Intern Med* 154: 1443-8
- Amos CI (2007) Successful design and conduct of genome-wide association studies. *Hum Mol Genet* 16 Spec No. 2: R220-5
- Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, Collen D, Dahlback B, Carmeliet P (2001) Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. *Nat Med* 7: 215-21
- Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. *Clin Pharmacol Ther* 79: 291-302
- Arbini AA, Bodkin D, Lopaciuk S, Bauer KA (1994) Molecular analysis of Polish patients with factor VII deficiency. *Blood* 84: 2214-20
- Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ, Pascussi JM (2004) Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. *Hepatology* 40: 951-60
- Balding DJ (2006) A tutorial on statistical methods for population association studies. *Nat Rev Genet* 7: 781-91
- Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 21: 263-5
- Berkner KL (2000) The vitamin K-dependent carboxylase. *J Nutr* 130: 1877-80
- Berkner KL, Pudota BN (1998) Vitamin K-dependent carboxylation of the carboxylase. *Proc Natl Acad Sci U S A* 95: 466-71

- Berkner KL, Runge KW (2004) The physiology of vitamin K nutrition and vitamin K-dependent protein function in atherosclerosis. *J Thromb Haemost* 2: 2118-32
- Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Lorient MA (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. *Blood* 106: 135-40
- Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. *Pharmacogenomics* 8: 1545-1550
- Brenner B, Sanchez-Vega B, Wu SM, Lanir N, Stafford DW, Solera J (1998) A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. *Blood* 92: 4554-9
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanos A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 352: 1092-102
- Cain D, Hutson SM, Wallin R (1998) Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. *Thromb Haemost* 80: 128-33
- Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. *J Thromb Thrombolysis* 22: 191-7
- Cascorbi I, Gerloff T, John A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. *Clin Pharmacol Ther* 69: 169-74
- Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Deckmyn H (2000) Structural determinants within platelet glycoprotein Iba $\alpha$  involved in its binding to von Willebrand factor. *Platelets* 11: 373-8
- Cha PC, Mushiroda T, Takahashi A, Saito S, Shimomura H, Suzuki T, Kamatani N, Nakamura Y (2007) High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. *J Hum Genet* 52: 856-64
- Chan YC, Valenti D, Mansfield AO, Stansby G (2000) Warfarin induced skin necrosis. *Br J Surg* 87: 266-72
- Chen JM, Cooper DN, Chuzhanova N, Ferec C, Patrinos GP (2007) Gene conversion: mechanisms, evolution and human disease. *Nat Rev Genet* 8: 762-75
- Chen Y, Ferguson SS, Negishi M, Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. *J*

- Pharmacol Exp Ther 308: 495-501
- Cheverud JM (2001) A simple correction for multiple comparisons in interval mapping genome scans. *Heredity* 87: 52-8
- Clemetson KJ, Clemetson JM (2007) Collagen receptors as potential targets for novel anti-platelet agents. *Curr Pharm Des* 13: 2673-83
- Cohen SM, Rosenthal DS, Karp PJ (1968) Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine-provoked hemolysis. *JAMA* 205: 528-30
- Conlan MG, Bridges A, Williams E, Marlar R (1988) Familial type II protein C deficiency associated with warfarin-induced skin necrosis and bilateral adrenal hemorrhage. *Am J Hematol* 29: 226-9
- Constable S, Johnson MR, Pirmohamed M (2006) Pharmacogenetics in clinical practice: considerations for testing. *Expert Rev Mol Diagn* 6: 193-205
- Dahlback B (2005) Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. *J Intern Med* 257: 209-23
- Daly AK, King BP (2003) Pharmacogenetics of oral anticoagulants. *Pharmacogenetics* 13: 247-52
- D'Ambrosio D, Lecca P, Constantin G, Priami C, Laudanna C (2004) Concurrency in leukocyte vascular recognition: developing the tools for a predictive computer model. *Trends Immunol* 25: 411-6
- D'Ambrosio RL, D'Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V, Grandone E, Margaglione M (2004) Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. *Haematologica* 89: 1510-6
- D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. *Blood* 105: 645-9
- de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D (2005) Efficiency and power in genetic association studies. *Nat Genet* 37: 1217-23
- Delabar JM, Lamour Y, Gégonne A, Davous P, Roudier M, Nicole A, Ceballos I, Amouyel P, Stehelin D, Sinet PM (1986) Rearrangement of chromosome 21 in Alzheimer's disease. *Ann Genet* 29: 226-8
- Devadatta S, Gangadharam PR, Andrews RH, Fox W, Ramakrishnan CV, Selkon JB, Velu S (1960) Peripheral neuritis due to isoniazid. *Bull World Health Organ* 23: 587-98
- Devlin B, Roeder K, Bacanu SA (2001) Unbiased methods for population-based association studies. *Genet Epidemiol* 21: 273-84
- Drayer DE, Reidenberg MM (1977) Clinical consequences of polymorphic acetylation of basic drugs. *Clin Pharmacol Ther* 22: 251-8
- Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes. *Genet Epidemiol* 25: 115-21
- Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized

- drug therapy. *Annu Rev Med* 57: 119-37
- Emanuel BS, Saitta SC (2007) From microscopes to microarrays: dissecting recurrent chromosomal rearrangements. *Nat Rev Genet* 8: 869-83
- ENCODE Project Consortium (2004) The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science* 306: 636-40
- Engesser L, Broekmans AW, Briet E, Brommer EJ, Bertina RM (1987) Hereditary protein S deficiency: clinical manifestations. *Ann Intern Med* 106: 677-82
- Evans DA, White TA (1964) Human Acetylation Polymorphism. *J Lab Clin Med* 63: 394-403
- Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. *Science* 286: 487-91
- Fasco MJ, Principe LM (1980) Vitamin K1 hydroquinone formation catalyzed by a microsomal reductase system. *Biochem Biophys Res Commun* 97: 1487-92
- Feuk L, Carson AR, Scherer SW (2006) Structural variation in the human genome. *Nat Rev Genet* 7: 85-97
- Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. *Nat Rev Genet* 8: 657-62
- Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Sun W, Wang H, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, Tsunoda T, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. *Nature* 449: 851-61
- Fredman D, White SJ, Potter S, Eichler EE, Den Dunnen JT, Brookes AJ (2004) Complex SNP-related sequence variation in segmental genome duplications. *Nat Genet* 36: 861-6
- Fujita K, Sasaki Y (2007) Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. *Curr Drug Metab* 8: 554-62
- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. *Science* 296: 2225-9
- Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. *J Biol Chem* 276: 14581-7

- Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnic variability of oral anticoagulation. *Thromb Haemost* 94: 773-9
- Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. *Biochemistry* 33: 1743-52
- Goodbourn SE, Higgs DR, Clegg JB, Weatherall DJ (1983) Molecular basis of length polymorphism in the human zeta-globin gene complex. *Proc Natl Acad Sci U S A* 80: 5022-6
- Goring HH, Curran JE, Johnson MP, Dyer TD, Charlesworth J, Cole SA, Jowett JB, Abraham LJ, Rainwater DL, Comuzzie AG, Mahaney MC, Almasy L, Maccluer JW, Kissebah AH, Collier GR, Moses EK, Blangero J (2007) Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. *Nat Genet* 39: 1208-16
- Gould WR, Baxi SM, Schroeder R, Peng YW, Leadley RJ, Peterson JT, Perrin LA (2005) Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. *J Thromb Haemost* 3: 733-41
- Grant DJ, Bell DA (2000) Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: susceptibility to oxidative damage and cancer? *Mol Carcinog* 29: 198-204
- Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghorri MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, et al. (2006) The DNA sequence and biological annotation of human chromosome 1. *Nature* 441: 315-21
- Guasch JF, Cannegieter S, Reitsma PH, van't Veer-Korthof ET, Bertina RM (1998) Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. *Br J Haematol* 101: 32-9
- Guenther TM, Cai D, Wallin R (1998) Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle. *Biochem Pharmacol* 55: 169-75
- Hasegawa Y, Ando Y, Ando M, Hashimoto N, Imaizumi K, Shimokata K (2006) Pharmacogenetic approach for cancer treatment-tailored medicine in practice. *Ann N Y Acad Sci* 1086: 223-32

- Hasstedt SJ, Bovill EG, Callas PW, Long GL (1998) An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. *Am J Hum Genet* 63: 569-76
- Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA* 287: 1690-8
- Hughes HB, Biehl JP, Jones AP, Schmidt LH (1954) Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. *Am Rev Tuberc* 70: 266-73
- Hull RD, Pineo GF (1995) Current concepts of anticoagulation therapy. *Clin Chest Med* 16: 269-80
- Ingelman-Sundberg M, Rodriguez-Antona C (2005) Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. *Philos Trans R Soc Lond B Biol Sci* 360: 1563-70
- Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. *Pharmacol Ther* 116: 496-526
- Investigators AF (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 154: 1449-57
- Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S (2004) Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. *Drug Metab Pharmacokinet* 19: 1-14
- Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ (1998) Multiple sequence alignment with Clustal X. *Trends Biochem Sci* 23: 403-5
- Jeffreys AJ, Turner M, Debenham P (1991) The efficiency of multilocus DNA fingerprint probes for individualization and establishment of family relationships, determined from extensive casework. *Am J Hum Genet* 48: 824-40
- Jeffreys AJ, Wilson V, Wong Z, Royle N, Patel I, Kelly R, Clarkson R (1987) Highly variable minisatellites and DNA fingerprints. *Biochem Soc Symp* 53: 165-80
- Jiang W, Yu G, Liu P, Geng Q, Chen L, Lin Q, Ren X, Ye W, He Y, Guo Y, Duan S, Wen J, Li H, Qi Y, Jiang C, Zheng Y, Liu C, Si E, Zhang Q, Tian Q, Du C (2006) Structure and function of glucose-6-phosphate dehydrogenase-deficient variants in Chinese population. *Hum Genet* 119: 463-78
- Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. *Nat Rev Genet* 8: 253-62
- Jobling MA, Tyler-Smith C (2003) The human Y chromosome: an evolutionary marker comes of age. *Nat Rev Genet* 4: 598-612
- Kakar P, Lane D, Lip GY (2006) Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. *Chest* 130: 1296-9

- Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA (1993) Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. *Mol Pharmacol* 43: 234-9
- Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. *Pharmacol Ther* 73: 67-74
- Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004) Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. *Eur J Clin Pharmacol* 59: 803-7
- Kessler CM (2006) Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? *J Thromb Haemost* 4: 963-6
- Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. *Science* 315: 525-8
- Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerstrom-Fermer ME, Dellsen A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, Billing-Clason SM, Cardon LR, March RE (2007) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. *Pharmacogenomics J*
- Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. *Pharmacogenomics J* 7: 257-65
- Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K, Kwiatkowski D (1999) A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. *Nat Genet* 22: 145-50
- Kohlmeier M, Salomon A, Saupe J, Shearer MJ (1996) Transport of vitamin K to bone in humans. *J Nutr* 126: 1192S-6S
- Kohn MH, Pelz HJ (2000) A gene-anchored map position of the rat warfarin-resistance locus, *Rw*, and its orthologs in mice and humans. *Blood* 96: 1996-8
- Kohnke H, Sorlin K, Granath G, Wadelius M (2005) Warfarin dose related to apolipoprotein E (APOE) genotype. *Eur J Clin Pharmacol* 61: 381-8
- Kornecki E, Lenox RH, Hardwick DH, Bergdahl JA, Ehrlich YH (1987) Interactions of the alkyl-ether-phospholipid, platelet activating factor (PAF) with platelets, neural cells, and the psychotropic drugs triazolobenzodiazepines. *Adv Exp Med Biol* 221: 477-88
- Krijanovski Y, Proulle V, Mahdi F, Dreyfus M, Muller-Esterl W, Schmaier AH (2003) Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression. *Blood* 101: 4430-6
- Kristensen SR (2002) Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity. *Blood* 100: 2676-7

- Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet* 27: 383-91
- Läkemedelsindustriföreningen (2007) Akademi-FASS : förteckning över humanläkemedel. Läkemedelsindustriföreningen (LIF), Stockholm
- Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ (1998) Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. *Am J Clin Nutr* 67: 1226-31
- Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. *Am J Med* 95: 315-28
- Lander ES, Botstein D (1986) Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms. *Proc Natl Acad Sci U S A* 83: 7353-7
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissole SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, et al. (2001) Initial sequencing and analysis of the human genome. *Nature* 409: 860-921
- Larsen TB, Lassen JF, Dahler-Eriksen BS, Petersen PH, Brandslund I (1998) Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation. *Thromb Res* 92: 157-62
- Lawley WJ, Charlton AJ, Hughson EJ, Grundy HH, Brown PM, Jones A (2006) Development of a cell culture/ELISA assay to detect anticoagulant rodenticides and its application to analysis of rodenticide treated grain. *J Agric Food Chem* 54: 1588-93
- Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 279: 1200-5
- Lee C, Iafrate AJ, Brothman AR (2007) Copy number variations and clinical cytogenetic diagnosis of constitutional disorders. *Nat Genet* 39: S48-54
- Lehmann H, Ryan E (1956) The familial incidence of low pseudocholinesterase level. *Lancet* 271: 124



- Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *J Clin Invest* 102: 1016-23
- Levine MN, Raskob G, Landefeld S, Hirsh J (1995) Hemorrhagic complications of anticoagulant treatment. *Chest* 108: 276S-290S
- Li H (2001) A permutation procedure for the haplotype method for identification of disease-predisposing variants. *Ann Hum Genet* 65: 189-96
- Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. *Nature* 427: 541-4
- Ligtenberg MJ, Gennissen AM, Vos HL, Hilkens J (1991) A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA. *Nucleic Acids Res* 19: 297-301
- Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT (2007) Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on Warfarin. *Clin Pharmacol Ther*
- Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A (2007) Incidence and predictors of severe bleeding during warfarin treatment. *J Thromb Thrombolysis*
- Lindh JD, Kublickas M, Westgren M, Rane A (2004) Internet based clinical trial protocols -- as applied to a study of warfarin pharmacogenetics. *Br J Clin Pharmacol* 58: 482-7
- Lindqvist PG, Svensson PJ, Dahlback B, Marsal K (1998) Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss--a possible evolutionary selection mechanism. *Thromb Haemost* 79: 69-73
- Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S (2005) Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. *Clin Pharmacol Ther* 77: 365-72
- Loewen P, Sunderji R, Gin K (1998) The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines. *Can J Cardiol* 14: 717-26
- Lovett PS, Duvall EJ, Keggins KM (1976) *Bacillus pumilus* plasmid pPL10: properties and insertion into *Bacillus subtilis* 168 by transformation. *J Bacteriol* 127: 817-28
- Lucier GW, Lui EM, Lamartiniere CA (1979) Metabolic activation/deactivation reactions during perinatal development. *Environ Health Perspect* 29: 7-16
- Lupski JR (2007) Genomic rearrangements and sporadic disease. *Nat Genet* 39: S43-7
- Mahtani MM, Willard HF (1993) A polymorphic X-linked tetranucleotide repeat locus displaying a high rate of new mutation: implications for mechanisms of mutation at short tandem repeat loci. *Hum Mol Genet* 2: 431-7
- Manfioletti G, Brancolini C, Avanzi G, Schneider C (1993) The protein encoded by a growth arrest-specific gene (*gas6*) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. *Mol Cell Biol* 13:

4976-85

- Martinez-Gonzalez J, Badimon L (2007) Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. *Curr Pharm Des* 13: 2215-27
- Matsuda M, Sugo T, Sakata Y, Murayama H, Mimuro J, Tanabe S, Yoshitake S (1988) A thrombotic state due to an abnormal protein C. *N Engl J Med* 319: 1265-8
- McGehee WG, Klotz TA, Epstein DJ, Rapaport SI (1984) Coumarin necrosis associated with hereditary protein C deficiency. *Ann Intern Med* 101: 59-60
- Michels E, De Preter K, Van Roy N, Speleman F (2007) Detection of DNA copy number alterations in cancer by array comparative genomic hybridization. *Genet Med* 9: 574-84
- Mockenhaupt M, Schopf E (1996) Epidemiology of drug-induced severe skin reactions. *Semin Cutan Med Surg* 15: 236-43
- Molokhia M, McKeigue P (2006) EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. *Pharmacogenomics* 7: 633-8
- Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. *Proc Natl Acad Sci U S A* 97: 7500-2
- Munoz X, Sumoy L, Ramirez-Lorca R, Villar J, de Frutos PG, Sala N (2004) Human vitamin K-dependent GAS6: gene structure, allelic variation, and association with stroke. *Hum Mutat* 23: 506-12
- Mustard JF, Packham MA (1975) Platelets, thrombosis and drugs. *Drugs* 9: 19-76
- Nagar S, Blanchard RL (2006) Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. *Drug Metab Rev* 38: 393-409
- Nakagawa T, Kishino S, Itoh S, Sugawara M, Miyazaki K (2003) Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. *Br J Clin Pharmacol* 56: 664-9
- Nevins JR, Potti A (2007) Mining gene expression profiles: expression signatures as cancer phenotypes. *Nat Rev Genet* 8: 601-9
- Newman DL, Hoffjan S, Bourgain C, Abney M, Nicolae RI, Profits ET, Grow MA, Walker K, Steiner L, Parry R, Reynolds R, McPeck MS, Cheng S, Ober C (2004) Are common disease susceptibility alleles the same in outbred and founder populations? *Eur J Hum Genet* 12: 584-90
- Norbert PW, Roses AD (2003) Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications. *J Mol Med* 81: 135-40
- Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet* 74: 765-9
- Olson ST, Bjork I (1994) Regulation of thrombin activity by antithrombin and heparin. *Semin Thromb Hemost* 20: 373-409

- Ovcharenko I, Loots GG, Hardison RC, Miller W, Stubbs L (2004) zPicture: dynamic alignment and visualization tool for analyzing conservation profiles. *Genome Res* 14: 472-7
- Ozdemir V, Williams-Jones B, Glatt SJ, Tsuang MT, Lohr JB, Reist C (2006) Shifting emphasis from pharmacogenomics to theragnostics. *Nat Biotechnol* 24: 942-6
- Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR, Kautzer CR, Lee DH, Marjoribanks C, McDonough DP, Nguyen BT, Norris MC, Sheehan JB, Shen N, Stern D, Stokowski RP, Thomas DJ, Trulson MO, Vyas KR, Frazer KA, Fodor SP, Cox DR (2001) Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. *Science* 294: 1719-23
- Peacock E, Whiteley P (2005) Perlegen sciences, inc. *Pharmacogenomics* 6: 439-42
- Pennacchio LA, Rubin EM (2001) Genomic strategies to identify mammalian regulatory sequences. *Nat Rev Genet* 2: 100-9
- Permutt MA, Elbein SC (1990) Insulin gene in diabetes. Analysis through RFLP. *Diabetes Care* 13: 364-74
- Peterson S, Bigler J, Horner NK, Potter JD, Lampe JW (2005) Cruciferae interact with the UGT1A1\*28 polymorphism to determine serum bilirubin levels in humans. *J Nutr* 135: 1051-5
- Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM (2004) CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. *Clin Pharmacol Ther* 75: 198-203
- Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *Bmj* 329: 15-9
- Pirmohamed M, Park BK (2003) Cytochrome P450 enzyme polymorphisms and adverse drug reactions. *Toxicology* 192: 23-32
- Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe'er I, Burt NP, Blumenstiel B, Defelice M, Parkin M, Barry R, Winslow W, Healy C, Graham RR, Neale BM, Izmailova E, Roubenoff R, Parker AN, Glass R, Karlson EW, Maher N, Hafler DA, Lee DM, Seldin MF, Remmers EF, Lee AT, Padyukov L, Alfredsson L, Coblyn J, Weinblatt ME, Gabriel SB, Purcell S, Klareskog L, Gregersen PK, Shadick NA, Daly MJ, Altshuler D (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat Genet*
- Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. *Science* 274: 1197-9
- Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood* 100: 3484-8
- Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ,

- Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. *Nat Genet* 32: 666-9
- Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T (2004) CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study. *Clin Pharmacol Ther* 75: 386-93
- Rawlins MD, James OF, Williams FM, Wynne H, Woodhouse KW (1987) Age and the metabolism of drugs. *Q J Med* 64: 545-7
- Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR, Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Armengol L, Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME (2006) Global variation in copy number in the human genome. *Nature* 444: 444-54
- Reed GL, Houg AK, Fitzgerald ML (1999) Human platelets contain SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is phosphorylated after thrombin activation: implications for platelet secretion. *Blood* 93: 2617-26
- Reich DE, Gabriel SB, Altshuler D (2003) Quality and completeness of SNP databases. *Nat Genet* 33: 457-8
- Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. *PLoS Med* 2: e312
- Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. *Pharmacogenetics* 4: 39-42
- Riddell JP, Jr., Aouizerat BE, Miaskowski C, Lillicrap DP (2007) Theories of blood coagulation. *J Pediatr Oncol Nurs* 24: 123-31
- Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *N Engl J Med* 352: 2285-93
- Rieder MJ, Reiner AP, Rettie AE (2007) Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. *J Thromb Haemost* 5: 2227-34
- Rodriguez-Revenga L, Mila M, Rosenberg C, Lamb A, Lee C (2007) Structural variation in the human genome: the impact of copy number variants on clinical diagnosis. *Genet Med* 9: 600-6
- Rosand J, Hylek EM, O'Donnell HC, Greenberg SM (2000) Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. *Neurology* 55: 947-51
- Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective

- drugs. *Nat Rev Genet* 5: 645-56
- Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappégard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. *Nature* 427: 537-41
- Rost S, Fregin A, Koch D, Compes M, Muller CR, Oldenburg J (2004) Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. *Br J Haematol* 126: 546-9
- Routledge PA, Chapman PH, Davies DM, Rawlins MD (1979) Pharmacokinetics and pharmacodynamics of warfarin at steady state. *Br J Clin Pharmacol* 8: 243-7
- Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, Cotsapas C, Xie X, Byrne EH, McCarroll SA, Gaudet R, Schaffner SF, Lander ES, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Sun W, Wang H, Wang Y, Xiong X, Xu L, Wayne MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, et al. (2007) Genome-wide detection and characterization of positive selection in human populations. *Nature* 449: 913-8
- Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. *Nature* 409: 928-33
- Sadler JE (2004) *Medicine: K is for koagulation*. *Nature* 427: 493-4
- Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGenet systematic review and meta-analysis. *Genet Med* 7: 97-104
- Schalekamp T, Brasse BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. *Clin Pharmacol Ther* 80: 13-22
- Schuster I, Bernhardt R (2007) Inhibition of cytochromes p450: existing and new promising therapeutic targets. *Drug Metab Rev* 39: 481-99
- Schwartz S, Elnitski L, Li M, Weirauch M, Riemer C, Smit A, Green ED, Hardison RC, Miller

- W (2003) MultiPipMaker and supporting tools: Alignments and analysis of multiple genomic DNA sequences. *Nucleic Acids Res* 31: 3518-24
- Schwarz UI (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. *Eur J Clin Invest* 33 Suppl 2: 23-30
- Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. *N Engl J Med* 358: 999-1008
- Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F (2006) APOE genotype makes a small contribution to warfarin dose requirements. *Pharmacogenet Genomics* 16: 609-11
- Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. *Blood* 106: 2329-33
- Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. *Blood* 103: 2630-5
- Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF (2006) Development of a contemporary bleeding risk model for elderly warfarin recipients. *Chest* 130: 1390-6
- Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C, Ionescu-Tirgoviste C, Widmer B, Dunger DB, Savage DA, Walker NM, Clayton DG, Todd JA (2006) A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* 38: 617-9
- Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrle P, Mehall JM, Edwards TL, Dawson EP (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. *Pharmacogenomics* 5: 895-931
- Spek CA, Koster T, Rosendaal FR, Bertina RM, Reitsma PH (1995) Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. *Arterioscler Thromb Vasc Biol* 15: 214-8
- Spivakov M, Fisher AG (2007) Epigenetic signatures of stem-cell identity. *Nat Rev Genet* 8: 263-71
- Stella VJ, Nti-Addae KW (2007) Prodrug strategies to overcome poor water solubility. *Adv Drug Deliv Rev* 59: 677-94
- Stram DO (2004) Tag SNP selection for association studies. *Genet Epidemiol* 27: 365-74
- Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, Montgomery S, Tavare S, Deloukas P, Dermitzakis ET (2007) Population genomics of human gene expression. *Nat Genet* 39: 1217-24
- Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in

- the tolbutamide polymorphism. *Pharmacogenetics* 6: 341-9
- Sussman N WM, Butler T, Cali J, Riss T, Kelly J (2002) The predictive nature of high throughput toxicity screening using a human hepatocyte cell line. *Cell Notes*: 7-10
- Suttie JW (1980) Mechanism of action of vitamin K: synthesis of gamma-carboxyglutamic acid. *CRC Crit Rev Biochem* 8: 191-223
- Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. *Nat Med* 7: 584-90
- The International HapMap Consortium (2003) The International HapMap Project. *Nature* 426: 789-96
- The International HapMap Consortium (2005) A haplotype map of the human genome. *Nature* 437: 1299-320
- The International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of the human genome. *Nature* 431: 931-45
- The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447: 661-78
- Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, Donn R, Symmons D, Hider S, Bruce IN, Wilson AG, Marinou I, Morgan A, Emery P, Carter A, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Strachan D, Worthington J (2007) Rheumatoid arthritis association at 6q23. *Nat Genet*
- Tishkoff SA, Varkonyi R, Cahinhinan N, Abbes S, Argyropoulos G, Destro-Bisol G, Drousiotou A, Dangerfield B, Lefranc G, Loiselet J, Piro A, Stoneking M, Tagarelli A, Tagarelli G, Touma EH, Williams SM, Clark AG (2001) Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. *Science* 293: 455-62
- Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, Furukawa H, Nagashima M, Yoshino S, Mabuchi A, Sekine A, Saito S, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. *Nat Genet* 35: 341-8
- Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. *Cancer Res* 52: 797-802
- Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). *Br J Cancer* 75: 69-75
- Van de Water N, Tan T, Ashton F, O'Grady A, Day T, Browett P, Ockelford P, Harper P (2004) Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. *Br J Haematol* 127: 190-4
- van Wijk R, Nieuwenhuis K, van den Berg M, Huizinga EG, van der Meijden BB,

- Kraaijenhagen RJ, van Solinge WW (2001) Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. *Blood* 98: 358-67
- Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. *Thromb Haemost* 95: 205-11
- Versteeg HH, Ruf W (2007) Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. *J Biol Chem* 282: 25416-24
- Vigano S, Mannucci PM, Solinas S, Bottasso B, Mariani G (1984) Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. *Br J Haematol* 57: 213-20
- Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH (2005) Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. *Pharmacogenet Genomics* 15: 69-74
- Vogel F (1959) Moderne probleme der Humangenetik. *Ergeb Inn Med Kinderheild* 12: 52-125
- von Rosensteil NA, Adam D (1995) Macrolide antibacterials. Drug interactions of clinical significance. *Drug Saf* 13: 105-22
- Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. *Pharmacogenomics* 5: 262-70
- Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. *Hum Genet* 121: 23-34
- Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. *Pharmacogenomics* 7: 99-111
- Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, Wadelius C, Melhus H (2004) Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. *Pharmacogenomics* 4: 40-8
- Wahls WP, Wallace LJ, Moore PD (1990) Hypervariable minisatellite DNA is a hotspot for homologous recombination in human cells. *Cell* 60: 95-103
- Wajih N, Hutson SM, Wallin R (2007) Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction. *J Biol Chem* 282: 2626-35
- Wajih N, Sane DC, Hutson SM, Wallin R (2004) The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. *J Biol Chem* 279: 25276-83
- Wajih N, Sane DC, Hutson SM, Wallin R (2005) Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. *J Biol*



- Chem 280: 10540-7
- Walker FJ (1981) Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. *J Biol Chem* 256: 11128-31
- Wallin R, Gebhardt O, Prydz H (1978) NAD(P)H dehydrogenase and its role in the vitamin K (2-methyl-3-phytyl-1,4-naphthaquinone)-dependent carboxylation reaction. *Biochem J* 169: 95-101
- Wallin R, Hutson SM, Cain D, Sweatt A, Sane DC (2001) A molecular mechanism for genetic warfarin resistance in the rat. *FASEB J* 15: 2542-4
- Wallin R, Sane DC, Hutson SM (2002) Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. *Thromb Res* 108: 221-6
- Walton R, Kimber M, Rockett K, Trafford C, Kwiatkowski D, Sirugo G (2005) Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. *Nat Genet* 37: 915-6; author reply 916
- Wang WY, Barratt BJ, Clayton DG, Todd JA (2005) Genome-wide association studies: theoretical and practical concerns. *Nat Rev Genet* 6: 109-18
- Watala C, Golanski J, Kardas P (2003) Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients. *Thromb J* 1: 7
- Weiss P, Soff GA, Halkin H, Seligsohn U (1987) Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. *Thromb Res* 45: 783-90
- Westwood IM, Kawamura A, Fullam E, Russell AJ, Davies SG, Sim E (2006) Structure and mechanism of arylamine N-acetyltransferases. *Curr Top Med Chem* 6: 1641-54
- Whittaker P, Bumpstead S, Downes K, Ghori J, P D (2005) SNP Analysis by MALDI-TOF Mass Spectrometry. In: Celis J CN, Simons K, Small JV, Hunter T, Shotton D (ed) *Cell Biology: A Laboratory Handbook.*, 3 edn. Elsevier, Amsterdam
- Wittkowsky AK (2007) Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. *J Thromb Thrombolysis*
- Wu O, Sumii T, Asahi M, Sasamata M, Ostergaard L, Rosen BR, Lo EH, Dijkhuizen RM (2007) Infarct prediction and treatment assessment with MRI-based algorithms in experimental stroke models. *J Cereb Blood Flow Metab* 27: 196-204
- Wu SM, Stafford DW, Frazier LD, Fu YY, High KA, Chu K, Sanchez-Vega B, Solera J (1997) Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase. *Blood* 89: 4058-62
- [www.janusinfo.se](http://www.janusinfo.se) Janusinfo Drug Interactions. Läkemedelscentrum in Stockholm's county council
- [www.thomsonhc.com](http://www.thomsonhc.com) Thomson Micromedex® Healthcare Series. Greenwood Village, Colorado
- Wynne Jones D, Russell G, Allford SL, Burdon K, Hawkins GA, Bowden DW, Minaee S, Mumford AD (2004) Severe prekallikrein deficiency associated with homozygosity for an Arg94Stop nonsense mutation. *Br J Haematol* 127: 220-3

References.

---

Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. *Hum Mol Genet* 14: 1745-51